Jerry Keybl, senior vice-president, Biopharma Products and Strategy, Avantor, discusses innovations in biomanufacturing and ...

ESTEVE CDMO's acquisition of Regis Technologies expands its US API contract development and manufacturing services, enhancing ...

A new nuclear magnetic resonance method reveals real-time, coordinated changes in nanoemulsion drugs, improving noninvasive ...

The company’s FDA-approved first generic sertraline capsules secured a 180‑day exclusivity period, highlighting strategic generic development pathways.

Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the ...

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

The changes, required for safety labeling of all opioid drugs, will emphasize the risks with long-term use to combat misuse ...

Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target tumors without impacting other cells in the body.

The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.

Evolving trade policies and tariffs strain bio/pharmaceutical manufacturers, affecting profits and operational strategies.

In this podcast episode, we discuss sustainable approaches to such equipment and materials as medical propellants, flow ...

If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.